TY - JOUR
T1 - Rare ER protein misfolding-mistrafficking disorders
T2 - Therapeutic developments
AU - Hegde, Ramanath Narayana
AU - Subramanian, Advait
AU - Pothukuchi, Prathyush
AU - Parashuraman, Seetharaman
AU - Luini, Alberto
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The presence of a functional protein at the appropriate location in the cell is the result of the processes of transcription, translation, folding and trafficking to the correct destination. There are numerous diseases that are caused by protein misfolding, mainly due to mutations in the respective gene. The consequences of this misfolding may be that proteins effectively lose their function, either by being removed by the cellular quality control machinery or by accumulating at the incorrect intracellular or extracellular location. A number of mutations that lead to protein misfolding and affect trafficking to the final destination, e.g. Cystic fibrosis, Wilson's disease, and Progressive Familial Intrahepatic 1 cholestasis, result in proteins that retain partial function if their folding and trafficking is restored either by molecular or pharmacological means. In this review, we discuss several mutant proteins within this class of misfolding diseases and provide an update on the status of molecular and therapeutic developments and potential therapeutic strategies being developed to counter these diseases.
AB - The presence of a functional protein at the appropriate location in the cell is the result of the processes of transcription, translation, folding and trafficking to the correct destination. There are numerous diseases that are caused by protein misfolding, mainly due to mutations in the respective gene. The consequences of this misfolding may be that proteins effectively lose their function, either by being removed by the cellular quality control machinery or by accumulating at the incorrect intracellular or extracellular location. A number of mutations that lead to protein misfolding and affect trafficking to the final destination, e.g. Cystic fibrosis, Wilson's disease, and Progressive Familial Intrahepatic 1 cholestasis, result in proteins that retain partial function if their folding and trafficking is restored either by molecular or pharmacological means. In this review, we discuss several mutant proteins within this class of misfolding diseases and provide an update on the status of molecular and therapeutic developments and potential therapeutic strategies being developed to counter these diseases.
KW - ERAD
KW - Misfolding
KW - Mutations
KW - Trafficking
UR - http://www.scopus.com/inward/record.url?scp=85013174110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013174110&partnerID=8YFLogxK
U2 - 10.1016/j.tice.2017.02.001
DO - 10.1016/j.tice.2017.02.001
M3 - Review article
C2 - 28222887
AN - SCOPUS:85013174110
VL - 49
SP - 175
EP - 185
JO - Tissue and Cell
JF - Tissue and Cell
SN - 0040-8166
IS - 2
ER -